EA201291276A1 - Фармацевтические композиции, содержащие солифенацин - Google Patents

Фармацевтические композиции, содержащие солифенацин

Info

Publication number
EA201291276A1
EA201291276A1 EA201291276A EA201291276A EA201291276A1 EA 201291276 A1 EA201291276 A1 EA 201291276A1 EA 201291276 A EA201291276 A EA 201291276A EA 201291276 A EA201291276 A EA 201291276A EA 201291276 A1 EA201291276 A1 EA 201291276A1
Authority
EA
Eurasian Patent Office
Prior art keywords
soliphenacine
pharmaceutical compositions
compositions containing
solifenacin
complex
Prior art date
Application number
EA201291276A
Other languages
English (en)
Other versions
EA023294B1 (ru
Inventor
Тацунобу Йосиока
Макото Мураи
Хироаки Тасаки
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201291276A1 publication Critical patent/EA201291276A1/ru
Publication of EA023294B1 publication Critical patent/EA023294B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описана фармацевтическая композиция, содержащая комплекс солифенацина или его фармацевтически приемлемой соли и ионообменной смолы, и полимер на основе акриловых производных.
EA201291276A 2010-05-19 2011-05-18 Фармацевтическая композиция, содержащая солифенацин EA023294B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34631110P 2010-05-19 2010-05-19
PCT/JP2011/061376 WO2011145642A1 (ja) 2010-05-19 2011-05-18 ソリフェナシン含有医薬組成物

Publications (2)

Publication Number Publication Date
EA201291276A1 true EA201291276A1 (ru) 2013-05-30
EA023294B1 EA023294B1 (ru) 2016-05-31

Family

ID=44972988

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291276A EA023294B1 (ru) 2010-05-19 2011-05-18 Фармацевтическая композиция, содержащая солифенацин

Country Status (23)

Country Link
US (1) US9918970B2 (ru)
EP (1) EP2572717B1 (ru)
JP (1) JP5831449B2 (ru)
KR (1) KR20130093010A (ru)
CN (1) CN102905706A (ru)
AU (1) AU2011255951C1 (ru)
BR (1) BR112012029461A2 (ru)
CA (1) CA2799942C (ru)
CY (1) CY1117816T1 (ru)
EA (1) EA023294B1 (ru)
ES (1) ES2588008T3 (ru)
HR (1) HRP20160901T1 (ru)
HU (1) HUE029400T2 (ru)
IL (1) IL223113A0 (ru)
LT (1) LT2572717T (ru)
MX (1) MX2012013328A (ru)
PL (1) PL2572717T3 (ru)
PT (1) PT2572717T (ru)
RS (1) RS55044B1 (ru)
SI (1) SI2572717T1 (ru)
TW (1) TW201208684A (ru)
WO (1) WO2011145642A1 (ru)
ZA (1) ZA201208762B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942063A1 (en) 2014-05-06 2015-11-11 S.I.I.T. S.r.L. - Unipersonale Composition for fluidizing mucus comprising chitosan and copolymers
CN104133011A (zh) * 2014-07-01 2014-11-05 北京万全德众医药生物技术有限公司 液相色谱法分离分析琥珀酸索利那新中间体及其有关物质
WO2018154495A1 (en) 2017-02-24 2018-08-30 Ftf Pharma Private Limited Pharmaceutical composition of oral solution of muscarinic antagonist
UY38137A (es) * 2018-03-08 2019-07-31 Intas Third Party Sales 2005 S L Una forma de dosificación oral sólida farmacéutica de solifenacina
KR20210114271A (ko) 2020-03-10 2021-09-23 주식회사 종근당 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 함유하는 약제학적 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JPH075604A (ja) * 1993-06-18 1995-01-10 Konica Corp ハロゲン化銀写真感光材料
GB9402029D0 (en) 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
CZ302919B6 (cs) * 1999-07-14 2012-01-18 Schering-Plough Ltd. Vodný farmaceutický prostredek
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
WO2005092889A1 (ja) 2004-03-25 2005-10-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の固形製剤用組成物
US20080103171A1 (en) 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
EP2146693A2 (en) * 2007-04-11 2010-01-27 Dr. Reddy's Laboratories Ltd. Solifenacin compositions

Also Published As

Publication number Publication date
US9918970B2 (en) 2018-03-20
EP2572717B1 (en) 2016-06-15
MX2012013328A (es) 2013-02-01
RS55044B1 (sr) 2016-12-30
AU2011255951A1 (en) 2012-12-20
AU2011255951C1 (en) 2015-02-19
BR112012029461A2 (pt) 2017-03-01
ES2588008T3 (es) 2016-10-28
WO2011145642A1 (ja) 2011-11-24
KR20130093010A (ko) 2013-08-21
HUE029400T2 (en) 2017-03-28
LT2572717T (lt) 2016-09-26
JP5831449B2 (ja) 2015-12-09
PL2572717T3 (pl) 2016-12-30
EP2572717A1 (en) 2013-03-27
US20110288118A1 (en) 2011-11-24
AU2011255951B2 (en) 2014-08-14
CA2799942A1 (en) 2011-11-24
SI2572717T1 (sl) 2016-11-30
EP2572717A4 (en) 2013-11-20
EA023294B1 (ru) 2016-05-31
IL223113A0 (en) 2013-02-03
TW201208684A (en) 2012-03-01
ZA201208762B (en) 2014-02-26
JPWO2011145642A1 (ja) 2013-07-22
CA2799942C (en) 2018-07-17
CY1117816T1 (el) 2017-05-17
PT2572717T (pt) 2016-07-19
CN102905706A (zh) 2013-01-30
HRP20160901T1 (hr) 2016-10-07

Similar Documents

Publication Publication Date Title
PH12020550552A1 (en) Inhibitors of hepatitis c virus
CY1120480T1 (el) Ενωσεις πυραζολοπυριμιδινης
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
BR112013010018A2 (pt) inibidores de cdk
CL2015000829A1 (es) Inhibidores de histona desmetilasas
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201590518A1 (ru) Стабильные водные составы адалимумаба
EA201690127A1 (ru) Состав на основе ингибиторов syk
GB201106750D0 (en) Novel compounds
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
UA113541C2 (xx) Заміщені піролідин-2-карбоксаміди
BR112014025041B8 (pt) Composição farmacêutica
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
EA201591024A1 (ru) Димерные соединения
CY1117816T1 (el) Φαρμακευτικη συνθεση περιεχουσα σολιφενακινη
CL2013000069A1 (es) Compuestos derivados de heterociclos fusionados, moduladores s1p; composicion farmaceutica; y uso en enfermedades neurodegenerativas.
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU